爵士製藥 JAZZ 深 滬
等待開盤 10-11 09:30:00 美东时间
135.43
-2.720
-1.97%
華盛通- 最 高139.00
- 今 開138.71
- 成交量 48.78万股
- 最 低 135.28
- 昨 收 138.15
- 總市值 81.95亿
- 52周最高 148.0568
- 市盈率 靜 15.66
- 換手率 0.81%
- 52周最低 95.49
- 委 比 54.44%
- 總股本 6051.10万
- 歷史最高 194.73
- 量 比 0.65
- 振 幅 2.69%
- 歷史最低 31.87
- 每 手 1
- 風險率 10.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Implanet S.A. reports Q3 results
Implanet S.A. press release (OTC:IMPZY): Q3 Revenue of €2.91M. As of September 30, 2025, the Company had a cash position of €0.41 million. Nine-month 2025 revenue of €8.7 million, up +36% compared to ...
10-08 02:16
SciSparc And AutoMax Call Off Merger
SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation.
10-06 20:55
FDA Approves Lurbinectedin In Combination With Atezolizumab Or Atezolizumab And Hyaluronidase-tqjs For Extensive-Stage Small Cell Lung Cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lurbinectedin-combination-atezolizumab-or-atezolizumab-and-hyaluronidase-tqjs-extensive
10-03 03:35
美股大行评级 | 217美元！花旗上调阿里巴巴目标价；多家机构集体上调麦克森、美光科技等目标价
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4美元升至4.25美元；瑞穗：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至56美元
09-25 09:52
Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
In the preceding three months, 9 analysts have released ratings for Jazz Pharma...
09-24 22:01
Jazz Pharma's Xywav Shows Phase 4 Results Improving Sleep And Daytime Alertness In Narcolepsy, Hypersomnia Patients
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new real-world evidence and Phase 4 data reinforcing the value of Xywav® (calcium, magnesium, potassium, and sodium oxybates)
09-22 19:46
Jazz Pharmaceuticals’ ZW25 Study Update: A Potential Game-Changer in Cancer Treatment
Jazz Pharmaceuticals (($JAZZ)) announced an update on their ongoing clinical st...
09-13 00:30
Amneal wins FDA nod for generic targeting Jazz Pharma’s Xyrem
Amneal Pharmaceuticals (NASDAQ:AMRX) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its generic product targeting Jazz Pharmaceuticals’ (NASDAQ:JAZZ) sleep disorder th...
09-11 23:56
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
Amneal Pharmaceuticals近日宣布其Sodium oxybate口服溶液500 mg/mL仿制药获得美国FDA批准，该药参考Jazz Pharmaceuticals的Xyrem，用于治疗7岁及以上narcolepsy患者的cataplexy或过度日间嗜睡。这是FDA批准的首个Sodium oxybate仿制药，将扩大Amneal平价药品系列，并提升患者获得治疗的机会。Sodium oxybate作为narcolepsy的标准治疗药物，可改善夜间睡眠并显著减少cataplexy发作。Amneal此举将为患者、医疗提供者和支付方提供更实惠的选择。
09-11 12:00
Jazz Pharma's Modeyso Earns NCCN Category 2A Recommendation For Treating H3 K27M-Mutant High-Grade Glioma In Pediatric And Adult Patients
Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the United StatesJazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that Modeyso™ (dordaviprone)
09-09 19:48
